Novo Nordisk

STAT+ | What Novo Nordisk’s disappointing trial results mean for the obesity drug market

New data on Novo's drug candidate CagriSema raise questions about the long-standing edge the company has held in the obesity drug market.

By Elaine Chen

STAT+ | New York health insurer agrees to up to $100 million settlement over Medicare fraud tied to improper diagnoses

The insurer examined patient records to find money-making diagnoses and pressured doctors to sign off on them, according to the government's suit.

By Tara Bannow

STAT+ | Ionis wins FDA approval for a rare disease therapy that lowers triglycerides

Ionis has long partnered with larger pharma firms to develop and market its products, but the company is commercializing Tryngolza on its own

By Jonathan Wosen

ARIANA DREHSLER/AFP via Getty Images

Rapid spread of H5N1 bird flu through California dairy herds suggests unknown paths of transmission

Emergency declaration by California Gov. Gavin Newsom shows we don't fully know how the H5N1 bird flu is spreading in cattle, experts say

By Megan Molteni

STAT+ | FDA OKs novel device for non-invasive treatment of spinal cord injuries

Dutch company's ARC-EX System designed to restore mobility after spinal cord injury, delivers programmed stimulation via electrodes placed on back of neck.

By Timmy Broderick

Maternal mortality data is murky — but the crisis faced by new moms is clear

Maternal mortality issue long clouded by conflicting data, reporting methods. Experts say it's time to focus on the qualitative aspects of improving care.

By Annalisa Merelli

Chantal Heijnen for STAT

STAT’s most memorable photos of 2024

Photos of the year 2024: STAT editors unveil their favorite visual moments from the year's top health, science, and medical stories.

By Alissa Ambrose and Crystal Milner